Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia
American Society of Clinical Oncology Educational Book · 2023-06 · (43)
DOI: 10.1200/edbk_390010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2023-06. Verfasst von Simone E Dekker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Oregon Health & Science University, Portland, OR. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Oregon Health & Science University, Portland, OR.
- France Intergroupe des Leucémies Myéloïdes chroniques FiLMC, Hôpital Saint-Louis APHP, Paris, France.
- Service d'Hématologie Adulte, Hôpital Saint-Louis APHP, Paris, France.
- Laboratoire de Biologie Moléculaire, Hôpital Saint-Louis APHP, Paris, France.
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
ORCID-Profile: Michael Heuser
Zitieren
APA
Dekker, S. E., Rea, D., Cayuela, J. M., Arnhardt, I., Leonard, J., & Heuser, M. (2023). Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_390010
Vancouver
Dekker SE, Rea D, Cayuela JM, Arnhardt I, Leonard J, Heuser M. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book. 2023. doi:10.1200/edbk_390010
BibTeX
@article{Dekker2023,
author = {Dekker, Simone E and Rea, Delphine and Cayuela, Jean-Michel and Arnhardt, Isabell and Leonard, Jessica and Heuser, Michael},
title = {Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia},
journal = {American Society of Clinical Oncology Educational Book},
year = {2023},
number = {43},
doi = {10.1200/edbk_390010}
}
EUVIMED